| Literature DB >> 35456060 |
Seong Bin Park1, Yon Kyoung Park2, Min Woo Ha3, Kim D Thompson4, Tae Sung Jung5.
Abstract
Diarrheal diseases due to foodborne Escherichia coli are the leading cause of illness in humans. Here, we performed pathogenic typing, molecular typing, and antimicrobial susceptibility tests on seventy-five isolates of E. coli isolated from stool samples of patients suffering from foodborne diseases in Busan, South Korea. All the isolates were identified as E. coli by both biochemical analysis (API 20E system) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). The bacteria displayed entero-pathogenic E. coli (EPEC) (47.0%), entero-aggregative E. coli (EAEC) (33.3%), entero-toxigenic E. coli (ETEC) (6.6%), ETEC and EPEC (6.6%), EPEC and EAEC (4%), and ETEC and EAEC (2.7%) characteristics. The E. coli isolates were highly resistant to nalidixic acid (44.0%), tetracycline (41.3%), ampicillin (40%), ticarcillin (38.7%), and trimethoprim/sulfamethoxazole (34.7%); however, they were highly susceptible to imipenem (98.6%), cefotetan (98.6%), cefepime (94.6%), and chloramphenicol (94.6%). Although 52 strains (69.3%) showed resistance against at least 1 of the 16 antibiotics tested, 23 strains (30.7%) were susceptible to all the antibiotics. Nine different serotypes (O166, O8, O20, O25, O119, O159, O28ac, O127a, and O18), five genotypes (I to V, random-amplified polymorphic DNA), and four phenotypes (A to D, MALDI-TOF MS) were identified, showing the high level of heterogeneity between the E. coli isolates recovered from diarrheal patients in South Korea.Entities:
Keywords: E. coli; South Korea; antimicrobial susceptibility test; genotyping; pathotyping; phenotyping
Year: 2022 PMID: 35456060 PMCID: PMC9030120 DOI: 10.3390/pathogens11040385
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
O-serotyping and virulence gene distribution of E. coli isolates.
| Pathotypes (%) | Virulence Genes | Total No. of Isolates | O Serotype (Total No. of Isolates) |
|---|---|---|---|
| ETEC (6.6) |
| 5 | O25(3), O159(1), UN(1) |
| ETEC and EAEC (2.7) |
| 2 | O159(1), UN(1) |
| ETEC and EPEC (6.6) |
| 1 | O8(1) |
|
| 2 | UN(2) | |
|
| 2 | UN(2) | |
| EPEC (47.0) |
| 27 | O8(2), O18(2), O20(2), O55(1), O119(3), O125(1), O153(1), O166(2), O127a(2), O28ac(1), UN(10) |
|
| 2 | UN(2) | |
|
| 6 | O6(1), O153(1), UN(4) | |
| EPEC and EAEC (4.0) |
| 3 | O159(1), O169(1), UN(1) |
| EAEC (33.3) |
| 25 | O1(1), O8(1), O20(2), O25(1), O78(1), O166(4), O28ac(2), UN(13) |
UN: unknown.
Antimicrobial resistance rate of E. coli isolates.
| Antimicrobial (Abbreviations) | No. of Resistant Isolates (%) | No. of Intermediate Isolates (%) | No. of Susceptible Isolates (%) |
|---|---|---|---|
| Penicillins | |||
| Ampicillin (AM) | 30 (40.0) | 0 | 45 (60) |
| Ticarcillin (TIC) | 29 (38.7) | 1 (1.3) | 45 (60) |
| ß-Lactam/ß-Lactamase inhibitor combinations | |||
| Ampicillin/Sulbactam (SAM) | 12 (16.0) | 8 (10.7) | 55 (73.3) |
| Cephems | |||
| Cefazolin (CZ) | 6 (8.0) | 0 | 69 (92) |
| Cefepime (FEB) | 1 (1.3) | 3 (4.0) | 71 (94.6) |
| Cefotaxime (CTX) | 4 (5.3) | 2 (2.7) | 69 (92) |
| Cefotetan (CTT) | 1 (1.3) | 0 | 74 (98.6) |
| Cephalothin (CF) | 11 (14.7) | 19 (25.3) | 45 (60) |
| Phenicols | |||
| Chloramphenicol (C) | 4 (5.3) | 0 | 71 (94.6) |
| Fluoroquinolones | |||
| Ciprofloxacin (CIP) | 10 (13.3) | 4 (5.3) | 61 (81.3) |
| Aminoglycosides | |||
| Amikacin (AN) | 5 (6.6) | 1 (1.3) | 69 (92) |
| Gentamicin (GM) | 14 (18.7) | 3 (4.0) | 58 (77.3) |
| Carbapenems | |||
| Imipenem (IPM) | 1 (1.3) | 0 | 74 (98.6) |
| Quinolones | |||
| Nalidixic acid (NA) | 33 (44.0) | 1 (1.3) | 41 (54.6) |
| Tetracyclines | |||
| Tetracycline (TE) | 31 (41.3) | 0 | 44 (58.6) |
| Folate pathway inhibitors | |||
| Trimethoprim/sulfamethoxazole (SXT) | 26 (34.7) | 2 (2.7) | 47 (62.6) |
Antimicrobial resistance patterns of 75 E. coli isolates.
| No. of Antimicrobials | Resistance Patterns | No. of Isolates |
|---|---|---|
| 0 | - | 23 |
| 1 | SXT | 1 |
| CZ | 1 | |
| TE | 1 | |
| NA | 8 | |
| TIC | 2 | |
| AM | 1 | |
| 2 | TE, NA | 1 |
| TE, TIC | 1 | |
| AN, TE | 1 | |
| AN, NA | 1 | |
| 3 | AM, CF, SAM | 1 |
| TE, NA, TIC | 2 | |
| CF, NA, TIC | 1 | |
| C, TE, NA | 1 | |
| 4 | AM, SXT, NA, TIC | 1 |
| AM, SXT, TE, SAM | 1 | |
| AM, NA, SAM, TIC | 1 | |
| AM, SXT, TE, TIC | 3 | |
| AM, SXT, TE, NA | 1 | |
| 5 | AM, SXT, TE, NA, TIC | 2 |
| AM, CF, C, TE, TIC | 1 | |
| GM, SXT, C, NA, TIC | 1 | |
| AM, CF, CIP, IPM, TE | 1 | |
| AM, GM, CTT, SAM, TIC | 1 | |
| 6 | AM, CF, SXT, C, TE, TIC | 1 |
| AM, CIP, SXT, TE, NA, SAM | 1 | |
| AM, GM, SXT, TE, NA, TIC | 3 | |
| AM, CZ, CF, SXT, TE, NA | 1 | |
| AM, CF, SXT, TE, NA, TIC | 1 | |
| 7 | AM, GM, CIP, SXT, TE, NA, TIC | 3 |
| 8 | AM, GM, CIP, SXT, TE, NA, SAM, TIC | 2 |
| AM, GM, AN, CTX, CIP, SXT, TE, SAM | 1 | |
| AM, CZ, CF, AN, SXT, NA, SAM, TIC | 1 | |
| 10 | AM, CZ, CF, GM, AN, FEP, CTX, SXT, SAM, TIC | 1 |
| 11 | AM, CZ, CF, GM, CTX, CIP, SXT, TE, NA, SAM, TIC | 2 |
| Total | 35 patterns | 75 strains |
SXT (Trimethoprim/Sulfamethoxazole), CZ (Cefazolin), TE (Tetracycline), NA (Nalidixic acid), TIC (Ticarcillin), AM (Ampicillin), AN (Amikacin), CF (Cephalothin), SAM (Ampicillin/Sulbactam), C (Chloramphenicol), CIP (Ciprofloxacin), IPM (Imipenem), GM (Gentamicin), CTT (Cefotetan), CTX (Cefotaxime), FEB (Cefepime).
Figure 1UPGMA cluster of RAPD band patterns for 75 E. coli isolates. The analysis was performed using RAPD primer 5 of the Ready-To-Go-RAPD Analysis kit. Five clusters were generated at 76% of RAPD profile similarity value using Bionumerics software.
Figure 2Cluster analysis of MSP dendrogram generated by MALDI-TOF MS for E. coli isolates. The dendrogram was generated using MALDI Biotyper 3.0, and the distance level in the dendrogram was set at a maximal value of 1000. The scale below the dendrogram signifies the relative distances. The five clusters were made at the distance level of 500.
Correlation analysis between clustal analysis by MALDI-TOF MS and phylogroup analysis by RAPD.
| No. (%) of Strains | MALDI-TOF MS | ||||
|---|---|---|---|---|---|
| RAPD | A | B | C | D | Total N (%) |
| I | 3 (4.0) | - | - | 6 (8.0) | 9 (12.0) |
| II | - | 1 (1.3) | 2 (2.7) | 41 (54.6) * | 44 (58.7) * |
| III | 6 (8.0) | 1 (1.3) | 3 (4.0) | 1 (1.3) | 11 (14.7) |
| IV | - | 4 (5.3) | - | 2 (2.7) | 6 (8.0) |
| V | 2 (2.7) | 1 (1.3) | - | - | 3 (4.0) |
| None | 1 (1.3) | - | - | 1 (1.3) | 2 (2.7) |
| Total N (%) | 12 (16.0) | 7 (9.3) | 5 (6.7) | 51 (68.0) * | 75 (100) |
* Statistical significance was assessed by Chi-squared test (p < 0.05).